This article examines the history, current status, and potential future challenges in the development of drugs for female sexual dysfunction (FSD) from the perspective of the United States Food and Drug Administration. In particular, the article focuses on testosterone therapy for hypoactive sexual desire disorder (a component of FSD), and the role of the Division of Reproductive and Urologic Products in facilitating the development of safe and effective therapies for this indication.
Drug regulatory processes in the US and the role of the Food and Drug Administration
In 1938, the Federal Food, Drug, and Cosmetic Act (FDC Act) was enacted as the underlying law that empowers the regulatory authority of the United States Food and Drug Administration (US FDA). This act required that new drugs demonstrate safety before being marketed to the public. Its enactment was partially a reaction to the deaths of over 100 people, many of them children, after ingestion of Elixir of Sulfonamide, which contained a poison solvent, diethylene glycol. About 25 years later, approval in Western Europe of thalidomide, a sleeping pill that caused birth defects in thousands of newborns, solidified popular support for stronger drug regulations in the US. Fortunately, because of the good work of an FDA medical officer, Frances Kelsey, thalidomide was not approved at that time in the US.
The Kefauver-Harris amendments of the FDC Act were passed in 1962 soon after the tragic thalidomide incident primarily to ensure greater drug safety. These amendments also required that drug products demonstrate effectiveness. The term effectiveness refers to the regulatory determination that is made on the basis of clinical efficacy and other data. Efficacy, in a drug regulatory context, refers to the findings in adequate and well-controlled clinical trials. Sponsors of marketing applications are required to establish a drug's effectiveness by providing the agency with 'substantial evidence.' Substantial evidence generally consists of data from 'adequate and well-controlled clinical investigations. ' The determination of whether the clinical trial information presented by the applicant constitutes 'substantial evidence' is determined by 'experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved.' Experts, in this context, are FDA staff, often in consultation with outside advisors. These experts determine whether 'the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended or suggested in the labeling or proposed labeling thereof.' 1 The above description of the drug approval process defines roles for sponsors and the FDA that appear to be isolated from each other. While it is true that the FDA maintains an oversight and regulatory role vis-à-vis the pharmaceutical industry, recent policy has encouraged interaction between the agency, sponsors, academia and other scientists to expedite and advance the knowledge base that would result in increased availability of safe and effective drug products for the American public. 'The mission of the US FDA is in part to protect the public health by assuring the safety, efficacy and security of human and veterinary drugsy. FDA is also responsible for advancing the public health by helping to speed innovation that makes medicines more effective, safery and helping the public get the accurate, science-based information they need to use medicine to improve their health.' 2 Procedures that would result in implementation of the above policies were recently published by the FDA as a formal Guidance for Review Staff and Industry. Most of these procedures had been in place in the Division of Reproductive and Urologic Products (DRUP) for years.
The draft Guidance states that 'Effective interaction between FDA and applicants during product development prior to NDA/BLA submission is criticaly the review staff can provide valuable scientific and regulatory advice to the applicant during the product development phase, resulting in more efficient and robust development programs. Second, FDA staff can interpret the FDC Acty to help the applicant define adequate evidence of effectiveness (e.g. end points, study design, patient populations), safety (sample size dose response, assessment of drug-drug interactions, demographic differences) and qualityy. It is critical for the applicants to ascertain the Agency's views on the applicable statutory requirements well in advance of submission of a marketing application.' 3 
Formulating regulatory recommendations in an environment of evolving clinical science
Characterization of a condition or disease state and a metric to evaluate improvement are essential parameters to allow the study of a drug that is proposed for treatment. The design and conduct of clinical trials for conditions that have well characterized diagnostic criteria and established clinical end points pose significant challenges to those who plan and perform them. Conditions that are less well defined, with controversial end points, present much greater challenges. Finally, when the definition of the condition and the end points are evolving while the drug development process is ongoing, regulatory and scientific communications and decisions are subjected to the greatest challenges.
The latter situation best characterizes the evaluation of drugs for the treatment of female sexual dysfunction (FSD) over the past decade. In this milieu of changing definitions and evolving end points that assess the effectiveness of potential therapies, DRUP has acquired information from diverse sources on an on-going basis. One of the most valuable sources of new information has been meetings with sponsors of potential new drugs for the treatment of FSD. DRUP has also utilized more traditional sources of information such as publications, oral communications with experts in the field, and interactions with our own internal and external experts. The process is iterative, working toward improving the precision of the definition of the disorder and the assessments of both efficacy and safety. The goal is accurate risk/benefit information that permits patients and healthcare providers to make informed decisions about the effectiveness and safety of drug therapies. In the remainder of this review, we will discuss DRUP's scientific and regulatory management in the evolving area of FSD.
The draft (2000) Guidance for Industry for Clinical Development of Drugs for FSD
Interest in pharmacotherapy for FSD appeared to be stimulated by the approval of sildenafil in 1998. Efforts to formulate a generally accepted clinical definition and classification of FSD and its subcategories intensified, as did investigations to identify the etiology and pathophysiology of FSD. Many exploratory and pilot studies were conducted at that time to determine the effect of drugs on the physiologic parameters of the healthy and pathologic female sexual response. 4 During this period of exploration and investigation, intense discussions were occurring between DRUP and drug sponsors regarding clinical trial designs. These discussions included a recommendation by DRUP to develop and validate instruments to measure changes in parameters associated with female sexual dysfunction that would provide evidence of the effectiveness of potential drug therapies for FSD.
As mentioned previously, one of the responsibilities of the FDA is to facilitate development of drug products by providing guidance to sponsors. This is accomplished on an individual basis by direct interactions with sponsors as well as through public documents referred to as 'Guidance to Industry' that describe the agency's current thinking and recommendations on drug development for a particular medical disorder. Guidances are not binding on the drug developer or the FDA and an alternative approach may be used if such an approach satisfies the applicable statute, regulation, or both. If a sponsor wants to propose an alternative approach, DRUP should be contacted. In May 2000, DRUP Clinical nomenclature described in the draft guidance was broadly based on the DSM IV. In accordance with the DSM IV, four components of FSD were described and defined: decreased sexual desire, decreased sexual arousal, dyspareunia, and persistent difficulty in achieving orgasm. The diagnosis of FSD requires that one or a combination of these components is associated with distress to the woman. To obtain drug approval for the desired indication, both safety and effectiveness need to be demonstrated for the particular component of FSD.
Study populations may be limited to one of the following subgroups or other subgroups if response to therapy may differ: premenopausal, naturally menopausal, surgically menopausal, women on menopausal symptom therapy (MST), or women on hormonal contraception. To better define the population and increase the likelihood of demonstrating a treatment effect, it may be appropriate to exclude subjects with the following: relationship difficulties with the sexual partner, use of concomitant medications that adversely affect sexual function, and the presence of medical conditions that adversely affect sexual function of the woman or her partner.
End points in clinical trials should be clinically meaningful to the patient and directly related to the disorder being studied. At the time that the draft guidance for FSD was published, much of the research in this area focused on the measurement of physical genital changes or laboratory parameters that occur as components of a woman's sexual response. These measurements are considered 'surrogate end points.' 6 Surrogate end points have been accepted by the agency in some areas such as the well-established association between a reduction in blood pressure and a reduction in clinically significant adverse cardiovascular events. At the present time, however, the use of surrogate end points in Phase 3 trials for FSD is not acceptable to DRUP because the link between the surrogate (e.g., vaginal blood flow) and the meaningful clinical outcome (e.g. a satisfactory sexual event) has not been established. At the time of the writing of the draft guidance, there was a need to define clinically meaningful end points for clinical trials of FSD.
The clinical end point recommended in the 2000 draft guidance is a 'satisfactory and successful sexual event' determined by the woman participating in the trial as recorded in a daily diary. Although the guidance document remains unchanged, DRUP's advice to sponsors has been to evaluate satisfactory sexual events without attempting to capture whether or not such events are successful because of the difficulty in distinguishing what is satisfying from what is successful. Satisfactory sexual events, as defined in the guidance, included but were not limited to sexual intercourse, sexual intercourse resulting in orgasm, oral sex resulting in orgasm, and partner initiated or self-masturbation resulting in orgasm. More recent advice to sponsors does not include orgasm as a necessary component of a satisfactory sexual event. Effectiveness was to be demonstrated by statistically and clinically significant improvement in the event end point(s) over time in the active treatment arm compared to the placebo arm in two randomized and adequately controlled trials. The 2000 guidance stated that 'many of the diagnostic and treatment response instruments being developed for FSD are based on health-related quality of life (HRQL) claims. Although these instruments can be useful in providing supportive information, they most likely should not serve as primary end points for Phase 3 trials. End points based on HRQL claims should be linked to clinically meaningful end points as described above.'
Public statements by DRUP in 2002
At the October 2002 meeting of the International Society for the Study of Women's Sexual Health (ISSWSH), DRUP reported on its current regulatory and scientific thinking regarding development of drugs for FSD. Since the publication of the 2000 guidance, there have been increased activities related to the development of drug therapies for FSD such as meetings with drug sponsors and other experts in the topic, evaluation of new protocols and further education of FDA personnel. DRUP also increased its scrutiny of drug safety issues as drug development proceeded to advanced stages for some products. DRUP's experiences resulted in increasing clarity of some of the issues surrounding safety and efficacy.
Many issues that had not been previously addressed were under active discussion. Much of the discussion focused on hypoactive sexual desire disorder (HSDD), one of the components of FSD, and its treatment with testosterone. The issue of whether testosterone constituted 'replacement' or 'therapy' was discussed. The concept that serum testosterone concentrations could serve as a surrogate end point in Phase 3 trials was rejected. Methods of defining HSDD for the purpose of clinical trials, and indeed for clinical diagnostic purposes, included discussions of history and physical examination, Patient Reported Outcome (PRO) instruments, professional interviews, blood tests, and imaging studies. Progression in the area of defining HSDD occurred. Discussion regarding factors that might impact HSDD itself or its therapy included various types and modes of administration of menopausal symptom therapies (different types of estrogens or progestins, oral vs transdermal administration, etc.) and socio-cultural factors (country, ethnicity, religion, age, etc.). At the time of the 2002 DRUP statement, the primary end point recommended for Phase 3 trials was based on satisfactory sexual events. Sponsors were also encouraged to develop and validate appropriate PRO instruments that could be used in clinical trials for complementary co-primary or secondary end points. The recommendation was for two trials each of at least 6 months duration. The volume of safety data required for approval, however, was not well defined. The conclusion of the 2002 DRUP statement was that approval would be based on a risk/benefit analysis (as with all drugs). The determination of benefit is defined by the disease, the population and the therapeutic effect. The determination of risk is defined by the known and potential adverse effects and the severity of the adverse events associated with the drug therapy. Better defined safety and efficacy information yields increased confidence in a decision concerning approvability of a proposed therapy.
Advisory Committee meeting for a new drug application (NDA) for FSD
The Food and Drug Administration Advisory Committee for Reproductive Health Drugs meeting was held in December 2004 as a result of the first NDA for a FSD indication (a transdermal testosterone system (TTS) for treatment of HSDD in surgically menopausal women). The NDA was submitted by Procter & Gamble after extensive communication with DRUP throughout the clinical development program. The advisory committee meeting was held during a period when several highly publicized events had recently focused increased attention on the safety of drug products. In July 2002, the first published report of the Women's Health Initiative raised concerns about the long-term safety of socalled 'hormone replacement therapy.' 7 The results caused particular concern among women and their healthcare prescribers because there had been the general impression that this form of therapy was, overall, beneficial to women. At the time of the advisory committee meeting, there were concerns that long-term hormone therapy in post-menopausal women was potentially detrimental. In 2003, a great deal of concern was raised over the potential for suicidality among patients on selective serotonin reuptake inhibitors and this was followed by the withdrawal of rofecoxib in September of 2004. These events also raised specific scientific and regulatory issues regarding the safety standards for drug approval. Old debates were rekindled regarding the relative merits of epidemiologic vs randomized clinical trial safety data. Debates also ensued regarding the quality and quantity of safety data needed before drug approval to define risks of particular concern vs how much safety data could be allowed to be obtained post-approval to more precisely define these risks.
Efficacy
The advisory committee meeting in December 2004 reviewed the clinical trial data for a TTS for the treatment of HSDD in surgically menopausal women receiving concomitant estrogen therapy. Discussions and questions were to address both the safety and efficacy of the proposed therapy.
The sponsor conducted two randomized, placebocontrolled efficacy trials each of six months duration. To be included in the trials, women had to answer in the affirmative to the following five questions: (1) Was sex satisfactory before surgery? (2) Have you had a decrease in desire since surgery? (3) Have you had a decrease in sexual activity since surgery? (4) Are you distressed by these changes? (5) Would you like to see an increase in desire for sex and sexual activity? The primary end point was the change from baseline to the end of study in the number of satisfactory sexual events (SSEs) over the previous 4 weeks as recorded by the subject in a daily diary. Other end points studied were changes in sexual desire and personal distress related to decreased sexual desire as measured by PRO instruments. Table 1 summarizes the efficacy findings of the two randomized controlled trials described above.
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There was a statistically significant mean treatment effect above that of placebo of approximately one additional SSE per 4 weeks in each trial. For the other two end points, the mean treatment effect above that of placebo was an increase of five units in the desire scores and a decrease of six to seven units in the distress scores.
A blinded exit interview queried a subset of subjects by asking 'Considering everything that we have talked about today, would you say you experienced a meaningful benefit from the study patches?' Of those on TTS, 52% responded yes; of those on placebo 31% responded yes. Based on these responses and the change in number of SSEs for each of the subjects, a Receiver Operating Characteristic (ROC) analysis was used to determine the magnitude of change in the number of SSEs that best separated the distribution of women reporting a benefit from those reporting no benefit. Using this method, the minimal meaningful treatment effect (MMTE) was determined to be an increase of one SSE per 4 weeks.
A responder analysis was then performed based on this information with regard to SSEs. The difference in the proportions of women in the TTS and placebo groups that had an increase of at least one SSE per 4 weeks (proportion of TTS subjects minus proportion of placebo subjects) was approximately 15%. This observation suggests that for every 6 or 7 women treated with TTS, only one of these women would have a clinically meaningful increase in the number of SSEs above that seen in women treated with a placebo. Interestingly, if one defined the MMTE as an increase of two or three SSEs over four weeks (instead of one), there was only a small decrease in the differences in the proportion of women that responded while on TTS compared to that in the placebo group (see Figure 1) .
The advisory committee members were asked: 'Does the efficacy data represent a clinically meaning benefit above that of placebo for surgically menopausal women with HSDD who are taking concomitant estrogen?' The response was Yes-14, No-3.
Safety
The discussion of risk associated with the use of TTS for the treatment of HSDD focused on the longterm use of testosterone as well as the long-term use of estrogen with or without progestin. Regarding testosterone therapy, the FDA staff presented information on androgenic adverse events observed during the trials as well as data and literature that suggested possible increases in cardiac risk factors based on changes in blood pressure, weight, and serum concentrations of lipids, glucose and insulin in the TTS-treated subjects. The constellation of these changes suggested that some women treated with TTS might be at risk for developing metabolic syndrome, a condition associated with a significant increase in cardiovascular morbidity. Speculative arguments regarding an increase in breast cancer were also advanced. The risks associated with longterm use of estrogen and progestin therapy as demonstrated by the WHI study and perhaps contradictory epidemiologic studies were as controversial at the time of the advisory committee meeting as they are today. The FDA stated that the studies presented for evaluation were inadequate in terms of numbers of subjects and duration of treatment to accurately define the level of potential increased risk for adverse events of concern such as clinically serious cardiovascular morbidity. Limitations of the study design included a placebo-controlled portion of the trials that was only 6 months long and exclusion of women at higher risk such as those with diabetes and cardiac disease. Twelve month data with TTS was available for only 494 subjects and 18-month data was available for only 127 subjects. The sponsor argued that there was no significant difference in the incidence of clinically significant adverse events in the submitted data between placebo and TTS-treated subjects, that androgenic events were mild and rarely lead to withdrawal, and that laboratory values and other data did not suggest increased cardiovascular risk. The sponsor also argued that there was no valid evidence to suggest long-term testosterone therapy would lead to an increase risk of developing breast cancer.
The advisory committee members were asked two questions on the subject of safety: (1) 'Is this exposure (total number of women treated and duration of treatment) adequate to demonstrate long-term safety?' The response was: Yes -0, No -17. (2) 'Should these concerns or questions be studied before approval of the product?' The response was: Yes -17, No -0.
To date, there are no approved drugs for the treatment of HSDD.
Current thinking
The following discussion is specifically related to testosterone for the treatment of HSDD, although the general principles apply to other drugs. DRUP is currently recommending that efficacy be measured by the co-primary end points of number of SSEs (assessed by the patient and reported in a daily diary) and change in sexual desire (as assessed by a validated PRO instrument). Distress related to a decrease in sexual desire (as measured by a validated PRO instrument) should also be studied. The selection of primary end points has been vigorously debated and criticized by some. 8 There are those who believe that the desire and/or distress end points are more appropriate than the SSE end point. DRUP believes that the present recommendations are appropriate. As additional information is accumulated both internally and externally, reevaluation is always considered. It is interesting to note that in the data presented at the December 2004 advisory committee meeting, the increase in the SSE end point appeared to reflect as robust a therapeutic effect of testosterone as the improvement in the desire or distress end points.
All end points should be presented as mean change from baseline compared to placebo. A responder analysis is also encouraged along with a justification of the MMTE.
The long-term risk of cardiovascular events and breast cancer is of most concern in the safety assessment. A prospective placebo-controlled 'large simple' safety trial will likely provide a more precise assessment of the potential for increased risk associated with therapy than a case-controlled or other epidemiologic study design. The safety trial would need to be larger if assessing the risk in younger, as compared to older, women because of the reduced number of background or spontaneous events in younger women. Ruling out a smaller relative risk and the use of clinical rather than surrogate end points (e.g. breast cancer vs breast density) also would require a larger trial. The duration of the trial will be a function of the number of expected events over time and the latency with which the risk of interest is likely to appear following the onset of treatment. Therefore, a longer trial is likely to be needed for assessing the potential increase in breast cancer risk vs an increase risk in cardiovascular events.
After consultation with internal and outside experts subsequent to the December 2004 advisory committee meeting, DRUP has communicated its thinking to sponsors who have approached the division regarding the attributes of the 'large simple' safety trial referred to in the previous paragraph. This randomized, placebo-controlled trial would likely require treatment duration of 1-2 years to accurately detect increased cardiovascular risk and 5-6 years to accurately detect increased breast cancer risk. Power calculations indicate that thousands of women would have to be enrolled in this trial. Clearly, this would be a costly study. As there is a constant tension between the agency's desire for risk/benefit precision and the sponsor's time/cost consideration, DRUP encourages proposals from sponsors to improve the feasibility of conducting a large simple safety study of testosterone therapy for HSDD. A possible strategy could include the evaluation of sufficient data premarketing to rule out a specific magnitude of risk, thus supporting approval with additional postmarketing data to further define risk. Ideally, the post-marketing analysis would not adversely affect the overall benefit/risk profile as to negatively impact marketing status. Supportive epidemiologic and surrogate marker information could be helpful.
An update of the Draft Guidance for FSD is planned. Guidance recommendations are not binding on FDA or sponsors and alternative approaches are always considered. DRUP looks forward to productive interactions with all stakeholders in 
